ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Go back to ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
Bay National Corporation (AMEX: BAYN) Delayed: 0.01 --0 (-0%)
Previous Close $0.01    52 Week High $0.04 
Open $61.11    52 Week Low $0.03 
Day High $0.01    P/E 0.00 
Day Low $0.01    EPS $-8.34 
Volume 358,028       

Bay National Corporation (AMEX: BAYN) Delayed: 0.01 --0 (-0%)
Previous Close $0.01    52 Week High $0.04 
Open $61.11    52 Week Low $0.03 
Day High $0.01    P/E 0.00 
Day Low $0.01    EPS $-8.34 
Volume 358,028       

Bayer Aktiengesellschaft American Depositary Shares (AMEX: BAYRY) Delayed: 10.56 --0 (-0%)
Previous Close $10.56    52 Week High $135.54 
Open $10.56    52 Week Low $94.36 
Day High $10.56    P/E N/A 
Day Low $10.56    EPS $0.00 
Volume 3,582       

Bayer AG (AMEX: BAYZF) Delayed: 44.31 --0 (-0%)
Previous Close $44.31    52 Week High $135.00 
Open $44.31    52 Week Low $94.95 
Day High $44.31    P/E N/A 
Day Low $44.31    EPS $0.00 
Volume 1,137